Cytokinetics Net Worth
Cytokinetics Net Worth Breakdown | CYTK |
Cytokinetics Net Worth Analysis
Cytokinetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cytokinetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cytokinetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cytokinetics' net worth analysis. One common approach is to calculate Cytokinetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cytokinetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cytokinetics' net worth. This approach calculates the present value of Cytokinetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cytokinetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cytokinetics' net worth. This involves comparing Cytokinetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cytokinetics' net worth relative to its peers.
Enterprise Value |
|
To determine if Cytokinetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cytokinetics' net worth research are outlined below:
| Cytokinetics generated a negative expected return over the last 90 days | |
| Cytokinetics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.53 M. Net Loss for the year was (526.24 M) with loss before overhead, payroll, taxes, and interest of (146.22 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (414.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Cytokinetics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Why Is Cytokinetics, Incorporated Among the Worst Performing Biotech Stocks in 2024 - Yahoo Finance |
Cytokinetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cytokinetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cytokinetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cytokinetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cytokinetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cytokinetics backward and forwards among themselves. Cytokinetics' institutional investor refers to the entity that pools money to purchase Cytokinetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.2 M | Boxer Capital Llc | 2024-09-30 | 2.1 M | Vestal Point Capital Lp | 2024-06-30 | 2.1 M | Armistice Capital, Llc | 2024-06-30 | 2.1 M | Alliancebernstein L.p. | 2024-06-30 | 1.9 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.8 M | Partner Fund Management Lp | 2024-09-30 | 1.8 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.7 M | Blackrock Inc | 2024-06-30 | 14.7 M | Fmr Inc | 2024-09-30 | 12.1 M |
Follow Cytokinetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.63 B.Market Cap |
|
Project Cytokinetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.69) | (0.65) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | 1.36 | 1.43 |
When accessing Cytokinetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cytokinetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cytokinetics' profitability and make more informed investment decisions.
Evaluate Cytokinetics' management efficiency
Cytokinetics has return on total asset (ROA) of (0.3013) % which means that it has lost $0.3013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7215) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics' management efficiency ratios could be used to measure how well Cytokinetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 1.43 this year, although the value of Return On Tangible Assets will most likely fall to (0.67). At this time, Cytokinetics' Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 1.2 B this year, although the value of Non Current Liabilities Other will most likely fall to about 338.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (4.00) | (4.20) | |
| Tangible Book Value Per Share | (4.00) | (4.20) | |
| Enterprise Value Over EBITDA | (19.05) | (18.10) | |
| Price Book Value Ratio | (20.86) | (19.82) | |
| Enterprise Value Multiple | (19.05) | (18.10) | |
| Price Fair Value | (20.86) | (19.82) | |
| Enterprise Value | 318.6 M | 334.5 M |
Understanding the operational decisions made by Cytokinetics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 1.8 K | Revenue 3.2 M | Quarterly Revenue Growth 0.225 | Revenue Per Share 0.03 | Return On Equity (5.72) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytokinetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cytokinetics Corporate Filings
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Cytokinetics Earnings per Share Projection vs Actual
Cytokinetics Corporate Management
| John Esq | Associate VP | Profile | |
| Andrew Callos | Executive Officer | Profile | |
| Jeff Lotz | Vice Operations | Profile | |
| Steven Cook | Senior Operations | Profile | |
| Scott Jordan | Senior Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.